about
"Real-world" data on the efficacy and safety of lenalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma who were treated according to the standard clinical practice: a study of the Greek Myeloma Study Group.Prognostic value of serum beta2-microglobulin in patients with Waldenstrom's macroglobulinemia requiring treatment.Tc-99m Depreotide SPECT/CT depicts myocardial involvement in a case of thrombotic thrombocytopenic purpura.Ibrutinib for patients with rituximab-refractory Waldenström's macroglobulinaemia (iNNOVATE): an open-label substudy of an international, multicentre, phase 3 trial.Hypercalcemia remains an adverse prognostic factor for newly diagnosed multiple myeloma patients in the era of novel anti-myeloma therapies.Allogeneic stem cell transplantation for myelodysplastic syndromes with bone marrow fibrosis.Severe impairment of regulatory T-cells and Th1-lymphocyte polarization in patients with Gaucher disease.Achievement of complete remission predicts outcome of allogeneic haematopoietic stem cell transplantation in patients with chronic myelomonocytic leukaemia. A study of the Chronic Malignancies Working Party of the European Group for Blood and MarrowThe incidence of myelodysplastic syndromes in Western Greece is increasing.Pathophysiology and pharmacological targeting of tumor-induced bone disease: current status and emerging therapeutic interventions.A retrospective study of azacitidine treatment in patients with intermediate-2 or high risk myelodysplastic syndromes in a real-world clinical setting in Greece.Management goals for type 1 Gaucher disease: An expert consensus document from the European working group on Gaucher disease.Erythropoiesis-stimulating agents significantly delay the onset of a regular transfusion need in nontransfused patients with lower-risk myelodysplastic syndrome.Non hypoxia-related splenic infarct in a patient with sickle cell trait and infectious mononucleosis.Evaluation of a Bone Marrow Dysmyelopoiesis Immunophenotypic Index for the Diagnosis and Prognosis of Myelodysplastic Syndromes.Efficacy of Interferon A-2b monotherapy in Β-thalassemics with chronic hepatitis C.A phase 3 randomized placebo-controlled trial of darbepoetin alfa in patients with anemia and lower-risk myelodysplastic syndromes.Lack of survival improvement with novel anti-myeloma agents for patients with multiple myeloma and central nervous system involvement: the Greek Myeloma Study Group experience.Poly (ADP-ribose) polymerase 1 mRNA levels strongly correlate with the prognosis of myelodysplastic syndromesWhole transcriptome analysis of human erythropoietic cells during ontogenesis suggests a role of VEGFA gene as modulator of fetal hemoglobin and pharmacogenomic biomarker of treatment response to hydroxyurea in β-type hemoglobinopathy patientsCompeting risk survival analysis in patients with symptomatic Waldenström macroglobulinemia: the impact of disease unrelated mortality and of rituximab-based primary therapy.Technetium-99m depreotide imaging by single photon emission tomography/low resolution computed tomography in malignant lymphomas: comparison with gallium-67 citrate.PET/CT in primary mediastinal large B-cell lymphoma responding to rituximab-CHOP: An analysis of 106 patients regarding prognostic significance and implications for subsequent radiotherapy.Evaluation of the clinical relevance of the expression and function of P-glycoprotein, multidrug resistance protein and lung resistance protein in patients with primary acute myelogenous leukemia.Prolonged administration of erythropoietin increases erythroid response rate in myelodysplastic syndromes: a phase II trial in 281 patients.Survival, prognostic factors and rates of leukemic transformation in 381 untreated patients with MDS and del(5q): a multicenter study.Multiple myeloma in octogenarians: clinical features and outcome in the novel agent era.Clinical features, outcome, and prognostic factors for survival and evolution to multiple myeloma of solitary plasmacytomas: a report of the Greek myeloma study group in 97 patients.Expression of the regulatory cell cycle proteins p21, p27, p14, p16, p53, mdm2, and cyclin E in bone marrow biopsies with acute myeloid leukemia. Correlation with patients' survival.A randomized trial comparing intensified CNOP vs. CHOP in patients with aggressive non-Hodgkin's lymphoma.Prospective randomized comparison of vincristine, doxorubicin and dexamethasone (VAD) administered as intravenous bolus injection and VAD with liposomal doxorubicin as first-line treatment in multiple myeloma.Treatment with bortezomib-based regimens improves overall response and predicts for survival in patients with primary or secondary plasma cell leukemia: Analysis of the Greek myeloma study group.Increased serum CA-15.3 levels in patients with megaloblastic anemia due to vitamin B12 deficiency.Disease-related anemia in chronic lymphocytic leukemia is not due to intrinsic defects of erythroid precursors: a possible pathogenetic role for tumor necrosis factor-alpha.Labile plasma iron levels predict survival in patients with lower-risk Myelodysplastic syndromes.Impaired clonogenic growth of myelodysplastic bone marrow progenitors in vitro is irrelevant to their apoptotic state.Occupational, dietary, and other risk factors for myelodysplastic syndromes in Western Greece.Validation of the revised international prognostic scoring system (IPSS-R) in patients with lower-risk myelodysplastic syndromes: a report from the prospective European LeukaemiaNet MDS (EUMDS) registry.Correlation of SIN3A genomic variants with β-hemoglobinopathies disease severity and hydroxyurea treatment efficacy.Relative iron "overload" in offspring of patients with type 2 diabetes mellitus: a new component in the conundrum of insulin resistance syndrome?
P50
Q30657752-65356858-C15A-442B-9BD4-CE4BF8A9BA5DQ33373881-95F24C28-5DE5-4F5A-830B-74C9440AFBE4Q33382155-23CA8124-0FC5-4DCB-AECA-EAB079E72B4AQ33437577-6A052BA5-6B81-4928-B67F-9614F6155D7DQ33443274-7C3F4935-3AE4-46B2-859A-FAFF0BFB3217Q34543049-27E6A398-E1E5-4BC9-A09D-9C08D3B88C16Q35183107-21D4DB0C-E05A-4AA4-9362-C58DE1ADDDE3Q35714782-C7AD02C9-3E1C-4004-B3E1-5BB44E198693Q36907039-393352B9-1D68-4DB3-BD06-2A45B2B20B23Q37856334-F240563E-7052-4EA6-BEF3-8F69F17306D8Q38999351-86747F64-6023-40C8-B611-37AD8115A03BQ39169176-98F4861F-2DA2-4440-A7EC-C344337D4A28Q40437221-5C495827-AD16-43D3-B302-19AC142BFA03Q40603311-3DF6C796-641E-4BF9-9A18-BE10F69E4006Q40781123-948BC45B-039E-4A5B-90C5-4F882C52CE67Q41138345-F1062F82-BA2A-4329-88AF-8951F08C21D5Q41186581-2E97231F-C796-44B3-B228-8D87A8664FC4Q41288885-F83DB0E9-62C1-46CF-8CAB-B1119D7ABC43Q42048049-DF416D48-328F-49DB-979C-25754A7EEBAAQ42643812-8201A7ED-DDE1-445D-B519-8BF6211A8B77Q42910816-60A1C77C-1941-4C61-ABF2-FB40A350BBC0Q42924382-0D87C75B-4065-4B98-AF1C-B7B955DC1838Q43438554-91C86DFF-4892-4A78-B62B-0A66B407860FQ43832873-EF53E8F5-E9DA-4F78-B22E-14340F6B488FQ44051865-4CB0F88A-D1C0-4261-B59D-4DCBBAB1734BQ44086304-5EE9F0EE-35B8-4D54-A071-8AD58E191FA0Q44156581-CDC19E95-0640-4A9C-886B-D4BF40F5B62FQ44225650-B170FF4D-AD77-4092-A2CC-6545F5535081Q44383328-36B0819D-0C22-4F9E-9A23-22E0641912B5Q44455479-20F0CEE0-1519-445C-8667-035B0F2E40DDQ44508371-6EC406E3-0465-487B-95CF-5DF2310FB055Q44559311-7C79B89B-82B8-4AF2-9655-7DCA4737ECF5Q45267591-44182D43-01FF-4FB9-B757-F7B54E4054F2Q45997397-323A6399-4977-4316-9B97-D58F62CFF6EDQ46264493-365FB3A4-BA54-4B64-B9AD-FAA6F9585A97Q47327960-4161984C-DFF7-4C50-85F7-D62004104906Q48336293-69BFDBC8-26A5-4A26-A8F7-EBE0B37E9B1EQ49093244-3A7453CC-76EE-40B6-B0EB-68D59AC34BE0Q51371221-072A3F8E-3D87-4023-A802-D92D934274CFQ51488984-99A4B8A6-2247-4D35-90CC-34185E217924
P50
description
Forscher
@de
chercheur
@fr
investigador
@es
researcher
@en
ricercatore
@it
wetenschapper
@nl
研究者
@zh
name
A Symeonidis
@ast
A Symeonidis
@en
A Symeonidis
@es
A Symeonidis
@nl
type
label
A Symeonidis
@ast
A Symeonidis
@en
A Symeonidis
@es
A Symeonidis
@nl
prefLabel
A Symeonidis
@ast
A Symeonidis
@en
A Symeonidis
@es
A Symeonidis
@nl
P31
P496
0000-0002-3685-3473